We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
Read MoreHide Full Article
Allergan plc announced that a supplemental New Drug Application (sNDA) for its anti-infective drug, Avycaz, has been accepted and granted priority review by the FDA.
We remind investors that Avycaz is currently approved for the treatment of complicated urinary tract infections ("cUTI"), including pyelonephritis. The drug, in combination with metronidazole, is approved for treating complicated intra-abdominal infections ("cIAI").
The company is looking to get the label of the drug expanded to include hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP). A decision from the FDA is expected in first-quarter 2018.
Allergan shares are up 0.5% so far this year, outperforming the industry’s decline of 19.8% in the same period.
The sNDA submission was based on non-inferiority data from a pivotal REPROVE study, which evaluated safety and efficacy of Avycaz in adult patients with HABP/VABP. The study showed that Avycaz was non-inferior to meropenem in reducing death irrespective of cause.
The drug also showed in vitro (study in controlled environment outside human body) activity against certain gram negative bacteria, which causes HABP/VABP.
We remind investors that the FDA issued a refusal-to-file letter last month to the sNDA for Vraylar to expand its label to include negative symptoms associated with schizophrenia.
However, boosting its generic portfolio, the company received approval in September for the biosimilar version of Roche Holding AG’s (RHHBY - Free Report) cancer drug, Avastin for the treatment of five types of cancer.
Allergan carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Biogen Inc. (BIIB - Free Report) . While Regeneron sports a Zacks Rank #1 (Strong Buy), Biogen carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have increased from $13.84 to $14.99 for 2017 and from $15.79 to $16.65 for 2018 over the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 10.11%. The share price of the company has increased 25.9% year to date.
Biogen’s earnings per share estimates have moved up from $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 11.5% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
Allergan plc announced that a supplemental New Drug Application (sNDA) for its anti-infective drug, Avycaz, has been accepted and granted priority review by the FDA.
We remind investors that Avycaz is currently approved for the treatment of complicated urinary tract infections ("cUTI"), including pyelonephritis. The drug, in combination with metronidazole, is approved for treating complicated intra-abdominal infections ("cIAI").
The company is looking to get the label of the drug expanded to include hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP). A decision from the FDA is expected in first-quarter 2018.
Allergan shares are up 0.5% so far this year, outperforming the industry’s decline of 19.8% in the same period.
The sNDA submission was based on non-inferiority data from a pivotal REPROVE study, which evaluated safety and efficacy of Avycaz in adult patients with HABP/VABP. The study showed that Avycaz was non-inferior to meropenem in reducing death irrespective of cause.
The drug also showed in vitro (study in controlled environment outside human body) activity against certain gram negative bacteria, which causes HABP/VABP.
We remind investors that the FDA issued a refusal-to-file letter last month to the sNDA for Vraylar to expand its label to include negative symptoms associated with schizophrenia.
However, boosting its generic portfolio, the company received approval in September for the biosimilar version of Roche Holding AG’s (RHHBY - Free Report) cancer drug, Avastin for the treatment of five types of cancer.
Allergan PLC. Price and Consensus
Allergan PLC. Price and Consensus | Allergan PLC. Quote
Zacks Rank & Stocks to Consider
Allergan carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Biogen Inc. (BIIB - Free Report) . While Regeneron sports a Zacks Rank #1 (Strong Buy), Biogen carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have increased from $13.84 to $14.99 for 2017 and from $15.79 to $16.65 for 2018 over the last 60 days. The company pulled off positive earnings surprises in two of the trailing four quarters, with an average beat of 10.11%. The share price of the company has increased 25.9% year to date.
Biogen’s earnings per share estimates have moved up from $21.37 to $21.42 for 2017 and from $23.11 to $23.23 for 2018 over the last 60 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 6.41%. The share price of the company has increased 11.5% year to date.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>